Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lisata Therapeutics, Inc. - Common Stock (NQ: LSTA ) 2.940 +0.010 (+0.34%) Streaming Delayed Price Updated: 10:31 AM EDT, May 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 5,024 Open 2.800 Bid (Size) 2.610 (4) Ask (Size) 2.870 (1) Prev. Close 2.930 Today's Range 2.640 - 2.940 52wk Range 1.950 - 4.480 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 May 02, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma April 23, 2024 Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1 From Lisata Therapeutics, Inc. Via GlobeNewswire Performance YTD +5.75% +5.75% 1 Month -4.55% -4.55% 3 Month +8.89% +8.89% 6 Month +34.86% +34.86% 1 Year -9.54% -9.54% More News Read More Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma April 09, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Recap: Lisata Therapeutics Q4 Earnings February 29, 2024 Via Benzinga Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events April 03, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma March 21, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Life Science Virtual Investor Forum Presentations Now Available for Online Viewing March 08, 2024 From Virtual Investor Conferences Via GlobeNewswire Earnings Scheduled For February 29, 2024 February 29, 2024 Via Benzinga Lisata Therapeutics's Earnings Outlook February 28, 2024 Via Benzinga Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024 March 05, 2024 From Virtual Investor Conferences Via GlobeNewswire Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ March 04, 2024 From Virtual Investor Conferences Via GlobeNewswire Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update February 29, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Earnings Preview: Lisata Therapeutics November 01, 2023 Via Benzinga Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time February 22, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Present at BIO CEO & Investor Conference February 20, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme January 17, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy January 04, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma December 12, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Present at NobleCon19 Investor Conference November 28, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in Upcoming Conferences in November November 09, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time October 26, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide October 24, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer October 17, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in Upcoming Conferences in October September 28, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
